Ward Malcolm, Güntert Andreas, Campbell James, Pike Ian
Proteome Sciences plc, London, United Kingdom.
Ann N Y Acad Sci. 2009 Oct;1180:68-74. doi: 10.1111/j.1749-6632.2009.05018.x.
Biomarkers of brain disorders are urgently needed to aid diagnosis, monitor disease progression, and, as new medicines are introduced, detect the patient's response to treatment. Proteomics provides the opportunity to discover novel biochemical markers based on protein or peptide changes, either in concentration levels or post-translational modification status. There are many challenges associated with proteomics studies, and this article represents a review of the issues discussed during the proteomics breakout sessions held at the Biomarkers for Brain Disorders conference in Oxford in January 2009. Although to date, there are very few qualified biomarkers that have arisen as a result of proteomics efforts, we remain optimistic that proteomics will deliver biomarkers for brain disorders. To be successful, we need to recognize that such endeavors are likely to require multidisciplinary teams and continued collaboration between academia, the biotechnology industry, and the pharmaceutical sector.
迫切需要脑部疾病的生物标志物来辅助诊断、监测疾病进展，并且随着新药的推出，检测患者对治疗的反应。蛋白质组学提供了基于蛋白质或肽的变化（无论是浓度水平还是翻译后修饰状态）发现新型生化标志物的机会。蛋白质组学研究存在许多挑战，本文对2009年1月在牛津举行的脑部疾病生物标志物会议的蛋白质组学分组讨论会上所讨论的问题进行了综述。尽管迄今为止，通过蛋白质组学研究产生的合格生物标志物非常少，但我们仍然乐观地认为蛋白质组学将为脑部疾病提供生物标志物。要取得成功，我们需要认识到此类努力可能需要多学科团队以及学术界、生物技术产业和制药部门之间的持续合作。
